AlzeCure Receives an Additional Subscription Commitment of Approximately SEK 5 million in the Upcoming Rights Issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

STOCKHOLM, SE / ACCESS Newswire / June 17, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received an additional subscription commitment of SEK 5 million from Max Mitteregger Kapitalförvaltning AB in the Company's rights issue announced on June 16, 2025 (the "Rights Issue"), which is still subject to approval by the extraordinary general meeting on July 2. Should the issue be oversubscribed, the Company intends to utilize the Over-Allotment Option to accommodate this subscription.

In addition to previously entered subscription commitments, Max Mitteregger Kapitalförvaltning AB, which currently does not own any shares in the Company, has committed to subscribe for shares amounting to approximately SEK 5 million, corresponding to about 10 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors. In the event the issue is oversubscribed and the allocation under this additional subscription commitment cannot be fully allocated, the Company intends to utilize the Over-Allotment Option to accommodate this subscription, considering it a subscription from a strategic and/or qualified investor.

Advisors
AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue.

Important information
The information in this press release does not contain nor constitute an offer to acquire, subscribe for or in any other way trade with shares, warrants or other securities in AlzeCure. No measures have been taken and no measures will be taken in order to allow for an offer to the public in any other jurisdictions than Sweden. Offer to for the relevant persons to subscribe for shares in AlzeCure will only be made through the Annex IX which AlzeCure expects will be published around July 4, 2025.